Form 4: GeneDx CFO Kevin Feeley Sells Shares Under 10b5-1 Trading Plan

GeneDx's Chief Financial Officer, Kevin Feeley, sold a total of 27,040 shares of Class A Common Stock over two days, November 21st and 22nd, under a pre-arranged 10b5-1 trading plan.

Summary

• Kevin Feeley, the Chief Financial Officer of GeneDx Holdings Corp., executed multiple sales of Class A Common Stock on November 21st and 22nd, 2024.
• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on August 21, 2024.
• On November 21st, a total of 13,019 shares were sold in multiple transactions at weighted average prices ranging from $69.575 to $74.9651.
• On November 22nd, a total of 9,981 shares were sold in multiple transactions at weighted average prices ranging from $75.3443 to $77.403.
• The total number of shares sold was 27,040, reducing Feeley's direct holdings to 22,951 shares.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan. It is neither particularly positive nor negative, but rather a standard disclosure.

Risks

• The sale of shares by a high-ranking executive could be perceived negatively by the market, potentially impacting the stock price.
• The use of a 10b5-1 trading plan suggests the sales were pre-planned, but the market may still react to the news.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common in publicly traded companies. The use of a 10b5-1 plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a 10b5-1 trading plan is a common practice among executives at publicly traded companies, including those in the biotechnology sector like GeneDx.
• Similar filings are regularly made by executives at companies like Illumina, Exact Sciences, and Myriad Genetics, reflecting routine stock transactions under pre-arranged plans.
• The volume of shares sold is not unusual for an executive's planned transactions, and the price range is within the normal trading range for the stock.

Stakeholder Impact

• The sale of shares by the CFO could cause some short-term volatility in the stock price, but the long-term impact is likely to be minimal given the pre-planned nature of the transactions.
• Shareholders may be interested in the details of the transactions, but the disclosure is routine and does not indicate any change in the company's fundamentals.

Key Dates

Keywords

GeneDx, Kevin Feeley, SEC Form 4, insider trading, stock sale, 10b5-1 plan, Class A Common Stock, executive compensation